ResearcherHeidelberg UniversityNo recent work listed
Alexis B. Ulrich
Matched on ORCID iD 0000-0003-1469-2186; OpenAlex author ID A5067646340. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 4 papers
Papers 8
- Staging of pancreatic cancer based on the number of positive lymph nodes. Last author DOI 10.1002/bjs.10472↗
- Radical surgery of oligometastatic pancreatic cancer. Co-author DOI 10.1016/j.ejso.2016.10.023↗
- The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm observational study. Co-author DOI 10.1016/j.hpb.2017.07.007↗
- Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? First author DOI 10.1016/j.yasu.2017.03.001↗
- Borderline resectable pancreatic cancer. First author DOI 10.1016/j.canlet.2016.02.039↗
- Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Co-author DOI 10.1097/sla.0000000000001850↗
- Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlle… Co-author DOI 10.1080/2162402x.2014.1001217↗
- Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.2651↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Thilo Hackert · 6 shared papers, 2016–2017 · strength 0.49
- Paper Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? DOI 10.1016/j.yasu.2017.03.001↗
- Paper Borderline resectable pancreatic cancer. DOI 10.1016/j.canlet.2016.02.039↗
- Paper Staging of pancreatic cancer based on the number of positive lymph nodes. DOI 10.1002/bjs.10472↗
- Markus Wolfgang Büchler · 5 shared papers, 2016–2017 · strength 0.41
- Paper Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy? DOI 10.1016/j.yasu.2017.03.001↗
- Paper Borderline resectable pancreatic cancer. DOI 10.1016/j.canlet.2016.02.039↗
- Paper Radical surgery of oligometastatic pancreatic cancer. DOI 10.1016/j.ejso.2016.10.023↗
- Oliver Strobel · 4 shared papers, 2016–2017 · strength 0.28
- Paper Staging of pancreatic cancer based on the number of positive lymph nodes. DOI 10.1002/bjs.10472↗
- Paper Radical surgery of oligometastatic pancreatic cancer. DOI 10.1016/j.ejso.2016.10.023↗
- Paper The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm obser… DOI 10.1016/j.hpb.2017.07.007↗
- Christoph W. Michalski · 3 shared papers, 2016–2017 · strength 0.20
- Paper Radical surgery of oligometastatic pancreatic cancer. DOI 10.1016/j.ejso.2016.10.023↗
- Paper The TRIANGLE operation - radical surgery after neoadjuvant treatment for advanced pancreatic cancer: a single arm obser… DOI 10.1016/j.hpb.2017.07.007↗
- Paper Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. DOI 10.1097/sla.0000000000001850↗
- Christoph Springfeld · 2 shared papers, 2015–2016 · strength 0.09
- Paper Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. DOI 10.1097/sla.0000000000001850↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Ilaria Tarantino · 1 shared paper, 2017 · strength 0.08
- René Warschkow · 1 shared paper, 2017 · strength 0.08
- Bruno Martin Schmied · 1 shared paper, 2017 · strength 0.08
- Willem Niesen · 1 shared paper, 2017 · strength 0.07
- André L. Mihaljević · 1 shared paper, 2017 · strength 0.07
- Thomas Schmidt · 2 shared papers, 2014–2015 · strength 0.07
- Paper Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer. DOI 10.18632/oncotarget.2651↗
- Paper Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic… DOI 10.1080/2162402x.2014.1001217↗
- Dirk Jäger · 1 shared paper, 2016 · strength 0.06
- Andreas G. Niethammer · 1 shared paper, 2015 · strength 0.03
- Friedrich Hubertus Schmitz-Winnenthal · 1 shared paper, 2015 · strength 0.03
- Nicolas Hohmann · 1 shared paper, 2015 · strength 0.03
- Martin A. Schneider · 1 shared paper, 2014 · strength 0.03
- Massimiliano Mazzone · 1 shared paper, 2014 · strength 0.03
- Philipp Beckhove · 1 shared paper, 2015 · strength 0.03
- Frank Pianka · 1 shared paper, 2015 · strength 0.03
- Nuh N. Rahbari · 1 shared paper, 2014 · strength 0.03
- Moritz Koch · 1 shared paper, 2014 · strength 0.03
- Mathieu Pecqueux · 1 shared paper, 2014 · strength 0.03
- Ulla Klaiber · 1 shared paper, 2015 · strength 0.03
- Markus K. Diener · 1 shared paper, 2015 · strength 0.03
- Niels Halama · 1 shared paper, 2014 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.